zmanindc - looks like they are pulling coverage for brand and generic. Insurance companies seeing the risk of their policies to promote infringing on Vascepa use patent. Next, will we see the generics pulling their product as risk on infringing a nonfrivolous patent that covers over 93% of of all Rx' written
Nothing on their alternative list is approved for added CV protection when added to a statin. FDA may request clarification from Insurance Company. Amarin's legal team needs to give them a call.